ZOLINZA

Compare ZOLINZA  to:
Compare
Compare

Generic Name for ZOLINZA

Vorinostat 100mg; caps.

Legal Classification:

Rx

Pharmacological Class for ZOLINZA

Histone deacetylase inhibitor.

Manufacturer of ZOLINZA

Merck & Co., Inc.

Indications for ZOLINZA

Refractory cutaneous T-cell lymphoma.

Adult dose for ZOLINZA

Take with food. Swallow whole. 400mg once daily. If not tolerated, may reduce to 300mg once daily, then to 300mg once daily 5 days/week if needed. Continue until disease progression or not tolerated.

Children's dosing for ZOLINZA

<18yrs: not recommended.

Precautions for ZOLINZA

Renal or hepatic impairment. Monitor for DVT, pulmonary embolism. Correct electrolyte disturbances before starting therapy. Maintain adequate hydration. Diabetes. Monitor CBC, platelets, blood glucose, serum creatinine, electrolytes (esp. potassium, calcium, magnesium) every 2 weeks for 1st 2 months, then monthly. Pregnancy (Cat.D). Nursing mothers: not recommended.

Interactions for ZOLINZA

Increased risk of thrombocytopenia and GI bleed with other HDAC inhibitors (eg, valproic acid). Concomitant warfarin: monitor PT, INR.

Adverse Reactions for ZOLINZA

GI upset, fatigue, chills; thrombocytopenia, anemia (may need to modify dose or discontinue); anorexia, dysgeusia, pulmonary embolism, DVT, hyperglycemia.

How is ZOLINZA supplied?

Caps—120

Related Disease:

Lymphoma, cutaneous T-cell
Neoplasms

Related Resources

FDA cancer drug approval rate reviewed in JNCI

February 19, 2010

The FDA's Office of Oncology Drug Products approved 53 new indications for the use of oncology and hematology drugs and biologics from July 2005 to the end of 2007.

Phase 3 study of perifosine for metastatic colon cancer

February 03, 2010

Æterna Zentaris and Keryx Biopharmaceuticals announced agreement with the FDA regarding a Special Protocol Assessment on its Phase 3 trial for perifosine (KRX-0401) for the treatment of refractory metastatic colorectal cancer.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 3 trial of Tavocept for the treatment of lung adenocarcinoma

January 22, 2010

BioNumerik Pharmaceuticals announced the treatment of the first patients in their Phase 3 trial of Tavocept (BNP7787) for primary adenocarcinoma of the lung.

FDA approves addition of updated survival data and hepatic dosing to Velcade label

January 04, 2010

Millennium Pharmaceuticals announced that the FDA has approved an expanded label for Velcade (bortezomib) that includes long-term overall survival (OS) data from the VISTA trial as well as dosing recommendations for patients with hepatic impairment.